An open-label 2:1 randomized phase I/II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients with non-resectable metastatic colorectal cancer and k-ras wild type (VOLFI)
Projektleiter:
Finanzierung:
Industrie;
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of k-ras wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI (http://www.clinicaltrials.gov)
Schlagworte
Clinical Trial, Colorectal Cancer
Kontakt
Dr. Petra Büchner-Steudel
Martin-Luther-Universität Halle-Wittenberg
Universitätsklinik und Poliklinik für Innere Medizin I
Ernst-Grube-Str. 40
06120
Halle (Saale)
Tel.:+49 345 5572665
weitere Projekte
Die Daten werden geladen ...